近期,制药巨头礼来正式起诉四家远程医疗公司(Mochi Health、Fella Health、Willow Health和Henry Meds),指控其未经授权销售礼来减重药物Zepbound和糖尿病治疗药物Mounjaro的仿制复方制剂。图片来源:摄图网争议故事的开端,要追溯到替尔泊肽作为革命性药物的诞生。2022年5月,这一全球首个GIPR/GLP-1R双重激动剂以Mounjaro的商品名...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.